Bank of Montreal
ABCL icon

Bank of Montreal’s AbCellera Biologics ABCL Stock Holding History

Bank of Montreal’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-555,000
Closed -$5.46M – 4043
2022
Q1 		$5.46M Buy
+555,000
New +$5.25M ﹤0.01% 1443

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of Montreal's ABCL Position: Q2 2026 in Review

Bank of Montreal increased its AbCellera Biologics (ABCL) stake by 166% in Q2 2026, buying an estimated $1.47M and bringing the position to 482,799 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

Bank of Montreal first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. 104 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Bank of Montreal held 482,799 shares of AbCellera Biologics worth $3.79M as of Q2 2026.
  • Bank of Montreal bought 301,109 AbCellera Biologics shares in Q2 2026, an estimated $1.47M.
  • AbCellera Biologics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1473 holding.
  • Bank of Montreal first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • 104 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.